Navigation Links
Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant
Date:7/30/2014

SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system.

The study shows that post-transplant treatment with C1-INH results in significant increases in the levels of complement components 3 and 4, suggesting that C1-INH inhibits activation of the complement system following transplantation. Antibody-mediated rejection is a major cause of kidney transplant failure and is often associated with activation of complement, a set of proteins that work with antibodies and play a role in the development of inflammation and tissue damage.

"Antibody-mediated rejection is a severe form of rejection that can occur in patients who have undergone a kidney transplant," said Stanley C. Jordan, M.D., Kidney Transplant, Cedars-Sinai Medical Center in Los Angeles, and one of the study's investigators. "Our findings provide additional insight into how C1-INH affects complement activation and represent an important advance in the study of complement-targeting therapeutics."

The placebo-controlled, single-center study evaluated 20 highly sensitized patients, meaning they already had antibodies against donor organs. Subjects were randomized to receive either placebo or 20 IU/kg of C1-INH, administered intra-operatively, then twice a week for seven additional doses. Patients were desensitized with immunoglobulin and rituximab, decreasing the patient's antibody levels prior to transplant.

According to study findings, fewer patients who were administered C1-INH developed serious adverse events compared to those administered placebo (20 percent versus 30 percent). C1-INH functi
'/>"/>

SOURCE CSL Behring
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a ... address unmet medical needs in women,s health, today ... present at the Cantor Fitzgerald Inaugural Healthcare Conference ... 4:45 PM EDTLocation: , Le Parker Meridien Hotel, ... www.juniperpharma.com, under  ,Investor, or  click here ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... 29 Novavax, Inc.,(Nasdaq: NVAX ) today announced ... million by issuing common stock and warrants from its,existing ... certain current, new institutional shareholders and,affiliates of the Company ... of common stock and a warrant to purchase 0.5 ...
... Developed as an Antipsychotic Agent with Less Potential for ... Treatment-Associated Weight Gain and Metabolic Risks, SAN DIEGO, ... today announced that the United States Patent and,Trademark Office ... that would provide broad coverage for a pharmaceutical,composition of ...
... 29 Scimitar Equity, LLC issues a ... VOQP), entitled, "510k,Application Submitted for Xyfid(TM) and ... Share Price Appreciation.", This review is ... VioQuest Pharmaceuticals is a New Jersey-based biotechnology ...
Cached Biology Technology:Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants 2Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants 3Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants 4OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... transplanted trees must endure from the time they are ... stress factors can mean the difference between survival and ... dug prior to transport, the majority of the root ... initial stress, trees are typically taken to a loading ...
... University geoscientist who has stirred controversy with her studies ... the dinosaurs has compiled powerful new evidence asserting her ... at many sites in the United States, Mexico and ... a vast meteorite, were the more likely culprits in ...
... Barro Colorado Island in Panama, home of the Smithsonian ... been described as the best-studied piece of tropical real ... been a mecca for biologists for nearly 90 years, ... the jaguaruntil now. , Montclair State University zoologist ...
Cached Biology News:Tree survival skills 2Tree survival skills 3Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 2Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 3Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 4First jaguar photo taken at Smithsonian Research Station in Panama 2
Hamster serum...
... Reactive Dye Pack, 12 x Cy5. ... optimized for microarray labeling.Higher reactivity Cy3 ... dye per vial, at > 75% ... dispensed, and packed in foil packs ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
Biology Products: